Table 4.
GEE-model with self-reported MET-hours per day as a measure of physical activity.
| Model 1 | Adjusted Model | |||
|---|---|---|---|---|
| B | P | B | P | |
|
LBM Menopausal status Use of HT Use of progestogen Follow-up time MET-hours/day Age |
−0.193 0.000 1.193 0.001 - - |
0.026 0.833 0.057 0.503 - - |
−0.203 0.000 1.263 0.001 0.053 0.109 |
0.019 0.836 0.050 0.420 0.036 0.506 |
|
LBMI Menopausal status Use of HT Use of progestogen Follow-up time MET-hours/day Age |
−0.069 0.000 0.290 0.000 - - |
0.029 0.696 0.110 0.426 - - |
−0.073 0.000 0.386 0.000 0.017 0.122 |
0.020 0.753 0.037 0.183 0.054 0.009 |
|
ALM Menopausal status Use of HT Use of progestogen Follow-up time MET-hours/day Age |
−0.231 0.001 0.555 0.001 - - |
<0.001 0.362 0.061 0.304 - - |
−0.238 0.001 0.557 0.001 0.038 0.025 |
<0.001 0.354 0.069 0.278 0.009 0.766 |
|
ALMI Menopausal status Use of HT Use of progestogen Follow-up time MET-hours/day Age |
−0.085 0.000 0.143 0.000 - - |
<0.001 0.386 0.083 0.200 - - |
−0.088 0.000 0.175 0.000 0.014 0.046 |
<0.001 0.326 0.039 0.082 0.005 0.055 |
|
Right leg lean mass Menopausal status Use of HT Use of progestogen Follow-up time MET-hours/day Age |
−0.088 0.000 0.214 0.000 - - |
0.001 0.398 0.054 0.224 - - |
−0.091 0.000 0.209 0.000 0.017 0.005 |
0.001 0.395 0.066 0.217 0.011 0.870 |
|
Absolute muscle area * Menopausal status Use of HT Follow-up time MET-hours/day Age |
−1.597 −0.001 −0.001 - - |
<0.001 0.811 0.833 - - |
−1.586 −0.001 0.000 0.047 0.236 |
0.001 0.797 0.938 0.801 0.748 |
|
Relative muscle area * Menopausal status Use of HT Follow-up time MET-hours/day Age |
−0.007 −1.5 × 10−5 −7.5 × 10−6 - - |
<0.001 0.488 0.716 - - |
−0.007 −6.7 × 10−6 −6.9 × 10−6 0.002 −0.002 |
<0.001 0.721 0.747 0.011 0.667 |
Model 1: adjusted for menopausal status, HT use in days, baseline use of progestogen and follow-up time in days. Adjusted model: adjusted for menopausal status, HT use in days, baseline use of progestogen, follow-up time in days, MET-hours/day and age at baseline. * Absolute and relative muscle areas were not adjusted for baseline progestogen use, as all participants were non-users at baseline. ALM, appendicular lean mass; ALMI, appendicular lean mass index; HT, hormone replacement therapy; LBM, lean body mass; LBMI, lean body mass index; MET, metabolic equivalent. Significant results (P ≤ 0.050) are shown in bold.